Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2017BloodOpen Access

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlison J. MoskowitzHSHeiko SchöderSGSomali Gavane

Discussion

Loading...

Member takes

Overview

Phase 2 trial reveals baseline metabolic tumor volume predicts event-free survival in relapsed or refractory Hodgkin lymphoma, highlighting its value for risk-stratified salvage therapy.

Key Points

  • Determine the prognostic value of baseline metabolic tumor volume in patients with relapsed or refractory Hodgkin lymphoma receiving PET-adapted salvage therapy.
  • Assessed patients enrolled in a phase 2 trial of PET-adapted salvage therapy combining brentuximab vedotin (BV) with augmented ifosfamide, carboplatin, and etoposide (augICE).
  • Evaluated the association of baseline metabolic tumor volume (bMTV) and pre-autologous stem cell transplantation (pre-ASCT) PET findings with clinical outcomes.
  • Baseline metabolic tumor volume (bMTV) and refractory disease status were identified as independent prognostic factors for event-free survival (EFS).
  • Patients with relapsed disease achieved a 3-year EFS of 100%, and among transplant recipients with positive pre-ASCT PET scans, those with low bMTV achieved an 86% 3-year EFS.
  • Incorporating bMTV substantially improved the prognostic accuracy of pre-ASCT PET response.

Cite This Study

Moskowitz et al. (2017) studied this question.

synapsesocial.com/papers/6a7caae321c5894b35c898ddhttps://doi.org/10.1182/blood-2017-06-788877
View Full Paper
Ask AI
Bookmark
Share